ClinicalTrials.gg
CompletedNCT03302091Updated Jun 4, 2021Results posted

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

A Phase 1 interventional study of BI 1467335 in Renal Insufficiency and Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-04.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Renal Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · Boehringer Ingelheim.

Enrollment
10th of 11
20 · median 35
Started
2017
the only one that year
Phase 1
10 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Renal Insufficiency by Boehringer Ingelheim, this one is the 10th largest by enrollment, is the only one that started in 2017, is one of 10 in phase 1, and was the 8th registered.

Renal Insufficiency

1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 11 studies in Renal Insufficiency by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Renal Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

The primary objective of the current study is to investigate the influence of moderate renal impairment on the pharmacokinetics of multiple doses in comparison to a matched control group with normal renal function.

03

Conditions studied

  • Renal Insufficiency
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Despite of moderate renal impairment (Group 1) healthy male or female subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), Pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Estimated (eGFR) based on CKD-EPI formula for Group 1 between 30 and 59 mL/min/1.73m2 and for Group 2 ≥ 90 mL/min/1.73m2
  • Age of 18 to 79 years (incl.)
  • of 18.5 to 34 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
  • Male subjects, or female subjects who meet any of the following criteria (according to the CTFG Recommendations related to and pregnancy testing in clinical trials, methods with a failure rate of less than 1% per year) starting from at least 30 days before the first administration of trial medication and until 30 days after trial completion, e.g.:

    • Use of adequate contraception, e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives (inhibition of ovulation)
    • Hormonal intrauterine device
    • Sexually abstinent (defined as refraining from heterosexual intercourse during the entire period of risk)
    • A vasectomised sexual partner (provided that vasectomy was performed at least 1 year prior to enrolment and the vasectomised partner has received medical assessment of the surgical success)
    • Surgically sterilised (including bilateral tubal occlusion, hysterectomy)
    • , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of FSH above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion criteria

Exclusion Criteria:

Healthy subjects

  • Any finding in the medical examination (including BP, PR or ) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Estimated (eGFR) calculated by CKD-EPI formula \< 90 mL/min/1.73m2

Subjects with moderate renal impairment

  • Subject with significant diseases other than moderate renal impairment. A significant disease is defined as a disease which in the opinion of the investigator:

    • puts the subjects at risk because of participation in the study
    • may influence the results of the study
    • may influence the subject's ability to participate in the study
    • is not in a stable condition Diabetic or hypertensive subjects can be entered in this trial if the disease is not significant according to these criteria.
  • Any finding of the medical examination (including BP, PR and ECG) of clinical relevance
  • Moderate and severe concurrent liver function impairment (e.g. due to hepatorenal syndrome) or biliary obstruction
  • Clinically relevant laboratory abnormalities (except for renal function tests or deviation of clinical laboratory values that are related to renal impairment)
  • eGFR calculated by CKD-EPI formula ≥ 60 mL/min/1.73m2 and \< 30 mL/min/1.73m2

For all subjects

  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 30 days prior to planned administration of trial medication or longer if required by local regulation, or within 5-half-lives of the investigational agent taken (whichever is longer), or current participation in another trial involving administration of investigational drug
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 20 g per day for females and 30 g per day for males)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  • Inability to comply with dietary regimen of trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males or repeatedly greater than 470 ms in females) or any other relevant ECG finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

Female subjects will not be allowed to participate if any of the following applies:

  • Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after study completion
  • Lactation period

Male subjects will not be allowed to participate if any of the following applies:

  • Male subjects with partner who are unwilling to use male (condom or sexual abstinence) from the first administration of trial medication until 30 days after last administration of trial medication
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    BI 1467335 Normal (R)

    Participants with normal renal function.

    Drug: BI 1467335

  • Experimental
    BI 1467335 Moderate (T)

    Participants with moderate renal impairment.

    Drug: BI 1467335

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)

    Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of the first dose AUC 0-24. Standard Error presented is actually geometric Standard Error. PKS-stat including participants data for AUC(0-24). The pharmacokinetic (PK) analysis set (PKS) included all subjects in the TS who provided at least one PK parameter that was defined as primary or secondary endpoint and who were not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.

    Time frame: Pharmacokinetic (PK) samples were taken 2.00 hours (h) before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 1.

  2. Maximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax)

    Maximum measured concentration of BI 1467335 in plasma after administration of the first dose (Cmax). Standard Error presented is actually geometric Standard Error.

    Time frame: Pharmacokinetic (PK) samples were taken 2.00 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 1.

  3. Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 28th Dose (AUCτ,28)

    Area under the concentration-time curve of BI 1467335 in plasma over the dosing interval after administration of the 28th dose (AUCτ,28). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: Pharmacokinetic samples were taken 0.0833 h before last dose and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 24.00 h after dosing on day 28.

  4. Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 28th Dose (Cmax,28)

    Maximum measured concentration of BI 1467335 in plasma following administration of the 28th dose (Cmax,28). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: Pharmacokinetic samples were taken 0.0833 h before last dose and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 24.00 h after dosing on day 28.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 14th Dose (AUCτ,14)

    Area under the concentration-time curve of BI 1467335 in plasma over the dosing interval after administration of the 14th dose (AUCτ,14). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: Pharmacokinetic samples were taken 0.0833 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 14.

  2. Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 14th Dose (Cmax,14)

    Maximum measured concentration of BI 1467335 in plasma following administration of the 14th dose (Cmax,14). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: Pharmacokinetic samples were taken 0.0833 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 14.

07

Results

Posted Jun 4, 2021

Participant flow

This was open-label, multiple-dose and matched-group design. 20 participants entered (ten in each of the two groups). Participants with moderate renal impairment were assigned to the moderate group and individually matched participants with normal renal function were assigned to the normal group.

Participant flow — Overall Study
MilestoneBI 1467335 Normal (R)BI 1467335 Moderate (T)
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)

Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of the first dose AUC 0-24. Standard Error presented is actually geometric Standard Error. PKS-stat including participants data for AUC(0-24). The pharmacokinetic (PK) analysis set (PKS) included all subjects in the TS who provided at least one PK parameter that was defined as primary or secondary endpoint and who were not excluded due to a protocol deviation relevant to the evaluation of PK or due to PK non-evaluability.

Time frame:
Pharmacokinetic (PK) samples were taken 2.00 hours (h) before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 1.
Reported as:
Geometric least squares mean · nanomole*hour/Liter (nmol*h/L)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)
nanomole*hour/Liter (nmol*h/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24)3.97 ± 1.317.88 ± 1.31
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 198.50 · 90% CI 101.83 to 386.94Standard deviation is actually intra individual geometric coefficient of variation (%).
PrimaryMaximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax)

Maximum measured concentration of BI 1467335 in plasma after administration of the first dose (Cmax). Standard Error presented is actually geometric Standard Error.

Time frame:
Pharmacokinetic (PK) samples were taken 2.00 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 1.
Reported as:
Geometric least squares mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax)
nanomole/Liter (nmol/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Maximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax)3.03 ± 1.246.01 ± 1.24
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 198.42 · 90% CI 116.56 to 337.78Standard deviation is actually intra individual geometric coefficient of variation (%).
PrimaryArea Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 28th Dose (AUCτ,28)

Area under the concentration-time curve of BI 1467335 in plasma over the dosing interval after administration of the 28th dose (AUCτ,28). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
Pharmacokinetic samples were taken 0.0833 h before last dose and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 24.00 h after dosing on day 28.
Reported as:
Geometric least squares mean · nanomole*hours/Liter (nmol*h/L)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 28th Dose (AUCτ,28)
nanomole*hours/Liter (nmol*h/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 28th Dose (AUCτ,28)692.42 ± 1.231566.88 ± 1.23
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 226.29 · 90% CI 156.35 to 327.53Standard deviation is actually intra individual geometric coefficient of variation (%).
PrimaryMaximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 28th Dose (Cmax,28)

Maximum measured concentration of BI 1467335 in plasma following administration of the 28th dose (Cmax,28). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
Pharmacokinetic samples were taken 0.0833 h before last dose and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 24.00 h after dosing on day 28.
Reported as:
Geometric least squares mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 28th Dose (Cmax,28)
nanomole/Liter (nmol/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 28th Dose (Cmax,28)100.57 ± 1.13141.20 ± 1.13
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 140.40 · 90% CI 108.06 to 182.43Standard deviation is actually intra individual geometric coefficient of variation (%).
SecondaryArea Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 14th Dose (AUCτ,14)

Area under the concentration-time curve of BI 1467335 in plasma over the dosing interval after administration of the 14th dose (AUCτ,14). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
Pharmacokinetic samples were taken 0.0833 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 14.
Reported as:
Geometric least squares mean · nanomole*hour/Liter (nmol*h/L)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 14th Dose (AUCτ,14)
nanomole*hour/Liter (nmol*h/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Dosing Interval After Administration of the 14th Dose (AUCτ,14)321.23 ± 1.34532.06 ± 1.34
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 165.63 · 90% CI 107.51 to 255.17Standard deviation is actually intra individual geometric coefficient of variation (%).
SecondaryMaximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 14th Dose (Cmax,14)

Maximum measured concentration of BI 1467335 in plasma following administration of the 14th dose (Cmax,14). Standard Error presented is actually geometric Standard Error. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
Pharmacokinetic samples were taken 0.0833 h before dosing and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 10.00, 12.00 and 23.917 h after dosing on day 14.
Reported as:
Geometric least squares mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 14th Dose (Cmax,14)
nanomole/Liter (nmol/L)BI 1467335 Normal (R)BI 1467335 Moderate (T)
Maximum Measured Concentration of BI 1467335 in Plasma Following Administration of the 14th Dose (Cmax,14)73.41 ± 1.1694.28 ± 1.16
Statistical analysis
  • BI 1467335 Normal (R) vs BI 1467335 Moderate (T) · ANOVA · Adjusted gmean ratio (t/r)%: 128.44 · 90% CI 99.64 to 165.57Standard deviation is actually intra individual geometric coefficient of variation (%).

Adverse events

Collected over From first day of study drug administration until End of trial (EOT), up to 41 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1467335 Normal (R)0/10 (0%)0/10 (0%)2/10 (20%)
BI 1467335 Moderate (T)0/10 (0%)0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventBI 1467335 Normal (R)BI 1467335 Moderate (T)
HeadacheNervous system disorders1/102/10
VomitingGastrointestinal disorders0/101/10
Rash pruriticSkin and subcutaneous tissue disorders1/100/10

Baseline characteristics

Treated Set (TS): The TS included all subjects who were documented to have taken at least one dose of trial medication. This is the full analysis set population in the sense of International council for harmonisation - efficacy guideline 9: statistical principles for clinical trials (ICH-E9).

Age, Continuous
Age, Continuous(Years)BI 1467335 Normal (R)BI 1467335 Moderate (T)Total
Mean67.5 ± 9.568.7 ± 10.968.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)BI 1467335 Normal (R)BI 1467335 Moderate (T)Total
Female448
Male6612
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 1467335 Normal (R)BI 1467335 Moderate (T)Total
Hispanic or Latino000
Not Hispanic or Latino101020
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1467335 Normal (R)BI 1467335 Moderate (T)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101020
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • CRS Clinical Research Services Kiel GmbH
    Kiel, 24105, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Aug 2018, 9 months.

Results were first posted in Jun 2021, 2 years 9 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2017
First posted
Oct 4, 2017
StartActual
Oct 17, 2017
Primary completionActual
Aug 16, 2018
CompletionActual
Aug 16, 2018
Results first posted
Jun 4, 2021
Last update
Jun 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03302091
Responsible party
Sponsor
First posted
Oct 4, 2017
Start date
Oct 17, 2017
Primary completion
Aug 16, 2018
Completion
Aug 16, 2018
Results posted
Jun 4, 2021
Last update
Jun 4, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PXS-4728A

Start the discussion